FRAX is a robust predictor of baseline vertebral fractures in multiple myeloma patients.


Journal

Bone
ISSN: 1873-2763
Titre abrégé: Bone
Pays: United States
ID NLM: 8504048

Informations de publication

Date de publication:
04 2019
Historique:
received: 23 05 2018
revised: 06 09 2018
accepted: 17 09 2018
pubmed: 24 9 2018
medline: 21 4 2020
entrez: 24 9 2018
Statut: ppublish

Résumé

FRAX is a commonly used tool to evaluate patient fracture risk based on individual patient models that integrate the risks associated with clinical risk factors with or without bone mineral density (BMD) at the femoral neck. Retrospectively, factors identified by the FRAX scoring algorithm were used to predict the risk for vertebral compression fractures at baseline in newly diagnosed multiple myeloma patients. The data were derived from myeloma patients enrolled in Total Therapy Protocols (TT4 & TT5) between 8/2008 and 9/2017. FRAX scores were calculated and baseline PET and MRI imaging obtained. Univariate and multivariate logistic regression analyses determined the association between FRAX components and the existence of vertebral compression fractures, both pathologic and osteoporotic. The patient population had a median age of 61 years (43-76), 37% female, and 87% white. The median major osteoporotic score (MOS) and Hip fracture scores (HFS) for TT4 patients (low-risk myeloma) were 5.6 and 0.5, respectively, while median MOS and HFS for TT5 (high risk myeloma) patients were 6.2 and 0.7, respectively. The odds ratio for fracture at diagnosis in patients with elevated MOS (>2), and HFS (>4.5) was significant OR (1.48, 95% confidence interval (1.35,1.62)) and OR (1.61, 95% confidence interval (1.42, 1.81)), respectively. In sum, an elevated baseline FRAX score was highly predictive of baseline vertebral fractures in MM patients at presentation. In addition, patients with higher FRAX scores had significantly shorter survival in the low-risk (TT4) group but this survival effect was not seen in the high-risk (TT5) group. These findings suggest that FRAX assessment of baseline fracture risk is beneficial in MM patients to identify an individual patients' risk of vertebral fracture.

Identifiants

pubmed: 30244157
pii: S8756-3282(18)30353-3
doi: 10.1016/j.bone.2018.09.013
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

134-138

Subventions

Organisme : NCI NIH HHS
ID : R01 CA166060
Pays : United States

Informations de copyright

Copyright © 2018. Published by Elsevier Inc.

Auteurs

Shebli Atrash (S)

Departement of Hematology Oncology, Levine Cancer Institute, Carolinas Health Care System, United States of America.

Isha Dua (I)

Departement of Hematology Oncology, Levine Cancer Institute, Carolinas Health Care System, United States of America.

Amy F Buros (AF)

Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America.

Fritz Van Rhee (F)

Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America.

Larry J Suva (LJ)

Department of Veterinary Physiology and Pharmacology, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, United States of America.

Sharmilan Thanendrarajan (S)

Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America.

Carolina Schinke (C)

Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America.

Faith Davies (F)

Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America.

Gareth Morgan (G)

Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America.

Maurizio Zangari (M)

Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America. Electronic address: Mzangari@uams.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH